The clinical studies included in the programme were evaluating the clinical efficacy of Pritor
®/Kinzal
® on
blood pressure control in two different kinds of populations in term of cardiometabolic risk:
- Patients in at-risk populations, such as the elderly, isolated systolic hypertension (ISH) patients or overweight/obese hypertensive patients with type 2 diabetes.
- Patients with various renal pathologies, such as endothelial dysfunction, microalbuminuria or mild to moderate overt nephropathy.
Click on the study names to read more about the clinical studies on www.ICMAedu.com
In at-risk patient populations, the
PROTECTION® programme showed that Pritor
®/Kinzal
® may induce:
- Sustained BP lowering throughout the critical morning period where CV risk is highest
- Renoprotective effects at every stage of the renal continuum
During the
PROTECTION® programme, Pritor
®/Kinzal
® met and sometimes exceeded the gold standards (ACEIs and other ARBs). Pritor
®/Kinzal
® was shown to be efficient in:
- Sustained BP reduction (PRISMA I and II)
- Elderly population
- Diabetes and Renal protection
- Left Ventricular Hypertrophy
For more information on the PROTECTION
® programme along with the data and opinions from leading experts on the potential implications for clinical practice, please visit
www.ICMAedu.com.
